Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Multiple Endocrine Neoplasias Type 2

Muhammad Yasir  1 , Neelam J. Mulji  2 , Anup Kasi  3
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Multiple Endocrine Neoplasias Type 2

Muhammad Yasir et al.
Free Books & Documents

Excerpt

Multiple endocrine neoplasia type 2 (MEN2), also known as Sipple syndrome, is a group of rare familial cancer syndromes involving multiple endocrine organs, most commonly thyroid, adrenal glands, and parathyroid. MEN2 was first described by Sipple in 1961 when he noticed a high association of bilateral pheochromocytomas with medullary thyroid cancer (MTC). Later, various other tissue and organ involvement was reported in areas that are not classically considered endocrine tissues like gut or skin. MEN2 is an autosomal dominant condition with very high penetrance and variable expressivity. Although MEN2 is rare, recognition is very important both for patient and family member evaluation and treatment.

MEN2 is further classified into two subcategories: MEN2A and MEN2B. Both types involve the thyroid and adrenal glands, but MEN2A also causes primary hyperparathyroidism (20 % to 30%). MEN2A is further categorized into the following four subtypes:

  1. Classical MEN2A

  2. MEN2A with cutaneous lichen amyloidosis (CLA)

  3. MEN2A with Hirschsprung disease (HD)

  4. Familial medullary thyroid cancer (FMTC)

In both MEN2A and MEN2B, there is an occurrence of multicentric tumor formation in all organs where RET proto-oncogene is expressed.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Muhammad Yasir declares no relevant financial relationships with ineligible companies.

Disclosure: Neelam Mulji declares no relevant financial relationships with ineligible companies.

Disclosure: Anup Kasi declares no relevant financial relationships with ineligible companies.

References

    1. Gagel RF, Levy ML, Donovan DT, Alford BR, Wheeler T, Tschen JA. Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med. 1989 Nov 15;111(10):802-6. - PubMed
    1. Siqueira DR, Ceolin L, Ferreira CV, Romitti M, Maia SC, Maciel LM, Maia AL. Role of RET genetic variants in MEN2-associated pheochromocytoma. Eur J Endocrinol. 2014 Jun;170(6):821-8. - PubMed
    1. Lips CJ, Landsvater RM, Höppener JW, Geerdink RA, Blijham G, van Veen JM, van Gils AP, de Wit MJ, Zewald RA, Berends MJ. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med. 1994 Sep 29;331(13):828-35. - PubMed
    1. Raue F, Frank-Raue K, Grauer A. Multiple endocrine neoplasia type 2. Clinical features and screening. Endocrinol Metab Clin North Am. 1994 Mar;23(1):137-56. - PubMed
    1. Albores-Saavedra JA, Krueger JE. C-cell hyperplasia and medullary thyroid microcarcinoma. Endocr Pathol. 2001 Winter;12(4):365-77. - PubMed

Publication types

LinkOut - more resources